These include our collaboration with Universal Cells, Inc. In addition to our internal next generation programs, to enable continued innovation and development, we also have collaborations with third parties intended to promote further next generation solutions.
We therefore have a number of next generation and combination SPEAR T-cell strategies designed to further develop and engineer our SPEAR T-cells in addition to the initiation of combination therapy approaches, the first of which is with Merck & Co., Incs (Merck) KEYTRUDA®. We also recognize that further development of our SPEAR T-cells may be assisted by an enhancement in efficacy and durability of response. Because of these uncertainties, you should not make any investment decision based on these estimates and forward-looking statements. In light of the risks and uncertainties described above, the estimates and forward-looking statements discussed in this Annual Report might not occur, and our future results and our performance may differ materially from those expressed in these forward-looking statements due to, inclusive of, but not limited to, the factors mentioned above.
Our future results may differ materially from those expressed in these estimates and forward-looking statements. Estimates and forward-looking statements involve risks and uncertainties and are not guarantees of future performance.
#AQ4 MAGE DROPS UPDATE#
Estimates and forward-looking statements speak only at the date they were made, and we undertake no obligation to update or to review any estimate and/or forward-looking statement because of new information, future events or other factors. The words believe, may, will, estimate, continue, anticipate, intend, expect and similar words are intended to identify estimates and forward-looking statements. Additional risks that we may currently deem immaterial or that are not presently known to us could also cause the forward-looking events discussed in this Annual Report not to occur. Additional factors that could cause actual results, financial condition, liquidity, performance, prospects, opportunities, achievements or industry results to differ materially include, but are not limited to, those discussed under Risk Factors in Part I, Item 1A in this Annual Report and in our other filings with the Securities and Exchange Commission (the SEC).
0 kommentar(er)
